TY  - JOUR
AU  - Del Pino Bellido, Pilar
AU  - Belvis Jiménez, María
AU  - Castro Laria, Luisa
AU  - Maldonado Pérez, María Belén
AU  - Sáez Díaz, Antonia
AU  - Caunedo Álvarez, Ángel
AU  - Argüelles-Arias, Federico
PY  - 2020
DO  - 10.17235/reed.2020.7130/2020
SN  - 1130-0108
UR  - http://hdl.handle.net/10668/15814
T2  - Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
AB  - vedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab. this was a retrospective study of inflammatory bowel disease (IBD) patients who received vedolizumab between...
LA  - en
KW  - Antibodies, Monoclonal, Humanized
KW  - Colitis, Ulcerative
KW  - Follow-Up Studies
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Inflammatory Bowel Diseases
KW  - Retrospective Studies
TI  - Vedolizumab response in inflammatory bowel disease. Two years of follow-up.
TY  - research article
VL  - 112
ER  -